{"groups":[{"description":"Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG000","title":"Phase I: X-396 (Ensartinib) at 25 mg"},{"description":"Dose escalation starting at 50 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG001","title":"Phase I: X-396 (Ensartinib) at 50 mg"},{"description":"Dose escalation starting at 100 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG002","title":"Phase I: X-396 (Ensartinib) at 100 mg"},{"description":"Dose escalation starting at 200 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG003","title":"Phase I: X-396 (Ensartinib) at 200 mg"},{"description":"Dose escalation starting at 225 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG004","title":"Phase I: X-396 (Ensartinib) at 225 mg"},{"description":"Dose escalation starting at 250 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase I: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG005","title":"Phase I: X-396 (Ensartinib) at 250 mg"},{"description":"Dose expansion starting at 225 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops\n\nPhase II: X-396 (ensartinib): Oral, ALK inhibitor","id":"FG006","title":"Phase II: X-396 (Ensartinib) at 225 mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"94"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"94"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 131 subjects were treated at 16 sites in the US, including 37 subjects in the escalation cohorts and 94 subjects in the expansion cohort."}